ASND — Ascendis Pharma A/S

Summary of Ascendis Pharma A/S Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: €248 million, including €187 million from Yorvipath and €53 million from Skytrofa.
• Full-Year 2025 Revenue: €720 million, with Yorvipath contributing €477 million and Skytrofa contributing €206 million.
• Operating Profit: €10 million for Q4, with an operating cash flow of €73 million.
• Total Operating Expenses: €214 million for Q4 and €761 million for the full year.
• Cash Position: Ended 2025 with €616 million in cash and cash equivalents, up from €560 million at the end of 2024.

2. Strategic Updates and Business Highlights

• Yorvipath: Strong global launch with over 5,300 patients prescribed by nearly 2,400 healthcare providers. The insurance approval rate reached 70%, with expectations for continued growth as more patients are initiated on treatment.
• Skytrofa: Continued solid performance with plans to expand its use in additional growth disorders. The Phase III trial for additional indications has been initiated.
• TransCon PTH: Approved in the US and EU for hypoparathyroidism, with ongoing efforts to broaden its label.
• Pipeline Development: Progress on TransCon CNP, with a PDUFA date set for February 28, 2026, and plans for a combination therapy with TransCon Growth Hormone.
• Global Expansion: Yorvipath launched in Japan and plans for commercial launches in 10 additional countries in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Expectations: Anticipated strong revenue growth for Yorvipath and Skytrofa, with an operating cash flow target of approximately €500 million.
• Long-Term Aspirations: Aim to achieve at least €5 billion in annual product revenue by 2030, supported by a robust pipeline and ongoing label expansions.

4. Bad News, Challenges, or Points of Concern

• Currency Impact: The weaker US dollar negatively affected revenues by approximately €27 million for Yorvipath and €9 million for Skytrofa in 2025.
• Insurance Approval Rate: While the current approval rate for Yorvipath is satisfactory, reaching 100% is deemed unrealistic, and the approval process may take time to improve further.
• Competitive Pressures: Concerns were raised regarding emerging competitors like encaleret and the potential impact of other agents in the hypoparathyroidism and achondroplasia markets, although management expressed confidence in their unique product offerings.

5. Notable Q&A Insights

• Confidence in TransCon CNP Approval: CEO Jan Moller Mikkelsen expressed strong confidence in the upcoming approval, likening it to previous successful approvals.
• Yorvipath Usage: Management noted broad uptake across various prescribers, with a significant portion of patients being self-aware of their conditions.
• Competitive Landscape: Moller Mikkelsen criticized competitor products, emphasizing the unique benefits of their hormone replacement therapies and expressing skepticism about the efficacy of emerging treatments.
• Launch Strategy for TransCon CNP: The company plans to leverage US approval for rapid international market entry, highlighting an established infrastructure for global commercialization.

This earnings call reflects Ascendis Pharma's strong financial performance and strategic positioning, while also acknowledging challenges related to currency fluctuations and competitive pressures. The company remains optimistic about future growth driven by its innovative product pipeline and expansion plans.